A prospective intervention study of the quality of life improvement effect of rifaximin administration in patients with non-alcoholic fatty liver disease (NAFLD) complicated by hyperammonemia with subclinical hepatic encephalopathy

Kazuhito Kawata0 个研究点目标入组 50 人开始时间: 2023年11月7日最近更新: 2023年11月20日

适应症

试验速览

暂无简介。

•1. Over 18-year-old and under 90-year-old
•2. Patients who have been diagnosed with non-alcoholic fatty liver disease (NAFLD) by diagnostic imaging or histological diagnosis
•3. Patients who are judged to be abnormal by the Stroop test or number connection test
•4. Patients whose ammonia levels exceed the upper limit of the institutional standard range (66 ug/dL)
•5. Those who have been able to obtain consent for participation in this research by signing a consent form by the person in question.

•1. Overt hepatic encephalopathy
•2. Positive for HCV antibodies
•3. Positive for HBs antigen or HBc antibody
•4. Positive for antinuclear antibodies or anti-mitochondrial antibodies
•5. Alcohol drinking more than 30 g of ethanol per day for men and 20 g of ethanol per day for woman
•6. Taking corticosteroids internally
•7. Undergoing hormone therapy for breast cancer
•8. Women who are pregnant or may become pregnant
•9. Color blindness
•10. Hypersensitive to rifaximin
•11. Taking cyclosporine or ethinyl estradiol internally
•12. The principal investigator or co-investigators deem it inappropriate to participate in this study.

发起方

Kazuhito Kawata